The distance from cornea to retina appears to be the difficult path for most of the small molecule therapeutics. Ocular drug delivery is extreme difficult task owing to complexity and intricate barriers of the eye. However, there is an urgency and need to overcome these barriers for the treatment of sight threatening ocular complications. Delivery of drugs through topical application is compromised by physiological, static, dynamic and metabolic barriers. Currently, intravitreal therapy is a gold standard for targeting therapeutic entities to the posterior segment of the eye. Promising treatment for eye conditions involves maintaining a long enough medication concentration at the eye. The barriers defending the eye prevent effective medication transport to the eye. The biggest challenge to overcome is frequently the active drug substance's bioavailability. Eye drops and other traditional ocular dose forms are insufficient to treat ocular illnesses nowadays. In near future, a great deal of attention will be paid to develop noninvasive sustained drug release for both anterior and posterior segment eye disorders. The development of novel drug delivery technologies is currently gaining steam, and this bodes well for the development of medicines for vision-threatening illnesses. Because topical delivery for ocular therapies requires less medication than systemic administration, acts quickly, and has no systemic toxicity, it is suitable. The interior portions of the eye must be reached by topically applied ocular medications, and transcorneal penetration is thought to be the main method of drug absorption.
IJMPR is an international open access source for a high quality and peer reviewed journal in the fields of Medical and Pharmaceutical Sciences. IJMPR publishes research papers across all academic disciplines in the fields of Medical, Pharmaceutical Sciences.